191162-30-8

Basic information

• Product Name: 2-(5-BroMo-pyridin-3-yloxyMethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester
• Synonyms: 2-(5-BroMo-pyridin-3-yloxyMethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester;(S)-2-(5-Bromo-pyridin-3-yloxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester
• CAS NO: 191162-30-8
• Molecular Formula: C₁₅H₂₁BrN₂O₃
• Molecular Weight: 357.24284
• Mol File: 191162-30-8.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(5-BroMo-pyridin-3-yloxyMethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-BroMo-pyridin-3-yloxyMethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester(191162-30-8)
• EPA Substance Registry System: 2-(5-BroMo-pyridin-3-yloxyMethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester(191162-30-8)

Safety Data

• Hazardous Substances Data: 191162-30-8(Hazardous Substances Data)

Usage

Molecular Structure

The compound consists of a pyrrolidine ring attached to a pyridine ring through an oxygen bridge, with a tert-butyl ester group located on the carboxylic acid moiety.

Functional Groups

The compound contains a tert-butyl ester functional group, a pyridine ring, and a pyrrolidine ring.

Bromine Content

The compound contains a bromine atom attached to the pyridine ring.

Potential Applications

The compound may have potential applications in the pharmaceutical and agrochemical industries as a building block for the synthesis of bioactive molecules.

Safety Protocols

It is important to handle and store this chemical with care, following proper safety protocols and guidelines for handling and disposal.

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 

Downstream Products

• 882170-01-6 (S)-2-[5-((E)-2-Pyridin-4-yl-vinyl)-pyridin-3-yloxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 299893-46-2 3-(1-BOC-2-(S)-Pyrrolidinyl-methoxy)-5-(4-pyridinyl-ethenyl)pyridine 
• 299893-21-3 3-(1-BOC-2-(R)-Pyrrolidinylmethoxy)-5-(4-chlorophenyl)pyridine 
• 1222139-94-7 3-[4-[2-(benzyloxy)ethyl]-1-piperidinyl]-5-[[1-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]pyridine 
• 1222140-30-8 3-[3(R)-[3-(benzyloxy)propyl]-1-pyrrolidinyl]-5-[[1-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]pyridine 
• 1246355-29-2 3-[[N-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]-5-[(N-ethyl-N-phenyl)amino]pyridine 
• 1246355-26-9 3-[[N-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]-5-phenylaminopyridine 
• 1246355-30-5 3-[[N-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]-5-[(N-methyl-N-benzyl)amino]pyridine 
• 1246355-27-0 3-[[N-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]-5-benzylaminopyridine 
• 1222138-45-5 3-[3-[5-[[1-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]-3-pyridyl]phenyl]-1-propanol 
• 1222136-38-0 3-[3(R)-[3-(benzyloxy)propyl]-1-pyrrolidinyl]-5-[(2(S)-pyrrolidinyl)methoxy]pyridine 

Relevant articles and documents

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF

The invention relates to pyridinyl nicotinic acetylcholine receptor ligands, compositions comprising an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand and methods to treat or prevent a condition, such as depression and nicotine dependence, comprising administering to an animal in need thereof an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand.

Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1- ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists

In order to advance therapeutic applications of nicotinic ligands, continuing research efforts are being directed toward the identification and characterization of novel nicotinic acetylcholine receptor (nAChR) ligands that are both potent and subtype selective. Herein we report the synthesis and pharmacological evaluation of members of a new series of 3-alkoxy-5- aminopyridine derivatives that display good selectivity for the α4β2-nAChR subtype based on ligand binding and functional evaluations. The most potent ligand in this series, compound 64, showed high radioligand binding affinity and selectivity for rat α4β2-nAChR with a Ki value of 1.2 nM and 4700-fold selectivity for α4β2- over α3β4-nAChR, and ～100-fold selectivity for functional, high-sensitivity, human α4β2-nAChR over α3β4*-nAChR. In the mouse forced swim test, compound 64 exhibited antidepressant-like effects. Structure-activity relationship (SAR) analyses suggest that the introduction of additional substituents to the amino group present on the pyridine ring of the N-demethylated analogue of compound 17 can provide potent α4β2-nAChR-selective ligands for possible use in treatment of neurological and psychiatric disorders including depression.